Pfizer Inc. $PFE Shares Sold by Aptus Capital Advisors LLC

Aptus Capital Advisors LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 15.7% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 163,146 shares of the biopharmaceutical company’s stock after selling 30,299 shares during the quarter. Aptus Capital Advisors LLC’s holdings in Pfizer were worth $4,157,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Pitcairn Co. boosted its position in Pfizer by 27.9% during the third quarter. Pitcairn Co. now owns 68,827 shares of the biopharmaceutical company’s stock worth $1,754,000 after acquiring an additional 15,013 shares during the last quarter. Crossmark Global Holdings Inc. raised its holdings in Pfizer by 0.9% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 72,857 shares of the biopharmaceutical company’s stock valued at $1,856,000 after acquiring an additional 676 shares during the last quarter. Integrated Quantitative Investments LLC purchased a new position in shares of Pfizer during the 3rd quarter worth $310,000. Winch Advisory Services LLC boosted its holdings in shares of Pfizer by 3.3% during the third quarter. Winch Advisory Services LLC now owns 18,080 shares of the biopharmaceutical company’s stock worth $461,000 after purchasing an additional 579 shares during the last quarter. Finally, Advisory Alpha LLC boosted its holdings in shares of Pfizer by 10.8% during the third quarter. Advisory Alpha LLC now owns 39,668 shares of the biopharmaceutical company’s stock worth $1,074,000 after purchasing an additional 3,882 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approved Pfizer’s GLP‑1 weight‑management drug (Xianweiying / ecnoglutide), opening a large new market for its obesity franchise and reinforcing Pfizer’s push into metabolic drugs — this expands addressable market and supports long‑term revenue potential. China approves Pfizer GLP-1 drug for weight management
• Positive Sentiment: Analyst upgrade: Argus Research upgraded PFE to Buy and set a $35 target, citing progress in the GLP‑1 program and oncology pipeline — this can attract buy interest and boost sentiment among dividend and income investors. Argus Turns Bullish on Pfizer
• Positive Sentiment: Oncology wins: positive Phase 3 EV‑304 PADCEV results and FDA full approval for BRAFTOVI combinations were highlighted as re‑framing Pfizer’s long‑term growth prospects in oncology — supports diversification away from COVID revenues. Pfizer Obesity Nod In China And Cancer Wins
• Positive Sentiment: Pipeline expansion in China: Pfizer launched a Phase 1 heart‑failure candidate study in China, signaling continued local R&D investment that could yield future launches in a large market. Pfizer Adds New Early-Stage Heart Failure Candidate
• Neutral Sentiment: Investor attention & valuation debate: multiple articles note heightened retail/institutional interest and divergent valuation views (trending stock coverage, DCF vs. long‑term return debates) — increases volatility/volume but not a direct fundamental change. Pfizer Is a Trending Stock
• Neutral Sentiment: Competition & generics risk for GLP‑1s: coverage notes Pfizer will face crowded competition (and price pressure risk) even as it gains approvals — a mixed commercial outlook. Weight-Loss Drug Approved in China — Up Against Generic Rivals
• Negative Sentiment: Structural headwinds remain: analysts reiterate risks from declining COVID revenues, upcoming patent expirations and U.S. drug‑pricing pressures (IRA) that could limit near‑term growth despite new launches. Can Pfizer Reignite Growth?
• Negative Sentiment: Policy/legal noise: a recent court ruling awarded Pfizer $29M in an SEC settlement dispute (one‑time benefit), but legal and policy developments remain sources of uncertainty for investors. Judge approves Pfizer, SEC settlement

Pfizer Trading Up 1.7%

PFE opened at $27.07 on Friday. The firm’s 50 day moving average is $26.30 and its 200-day moving average is $25.47. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.94. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $153.93 billion, a P/E ratio of 19.90 and a beta of 0.47.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same period last year, the business earned $0.63 EPS. The business’s revenue was down 1.2% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 6th. Stockholders of record on Friday, January 23rd were paid a dividend of $0.43 per share. The ex-dividend date was Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. Pfizer’s dividend payout ratio (DPR) is currently 126.47%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research note on Wednesday, February 4th. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a report on Thursday, February 12th. Scotiabank started coverage on shares of Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target on the stock. Morgan Stanley reduced their price target on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Friday, December 12th. Finally, Barclays started coverage on shares of Pfizer in a research note on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $28.05.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.